Printer Friendly

Algiax Pharmaceuticals Names Sommer, Klaus-Dieter Langner to Scientific Advisory Board.

M2 PHARMA-July 22, 2019-Algiax Pharmaceuticals Names Sommer, Klaus-Dieter Langner to Scientific Advisory Board

(C)2019 M2 COMMUNICATIONS

- Germany-based clinical-stage biotechnology company Algiax Pharmaceuticals has appointed Prof. Dr. med. Claudia Sommer and Dr. Klaus-Dieter Langner as members of Algiax'scientific advisory board, the company said.

Claudia Sommer is a Professor of Neurology at the University of Wurzburg, Germany, with a focus on peripheral neurology and pain.

She has written more than 250 original research papers and is active in the development of national and international guidelines on diagnosis and treatment of peripheral neuropathies, and on neuropathic pain.

As of Jan 2019, she is president of the German Pain Society and president elect of the International Society for the Study of Pain.

Klaus-D. Langner holds a Ph.d. in Molecular Biology from University of Cologne. He started his career at Behringwerke AG in 1986.

In 1998 he joined Gruenenthal GmbH as Head of Research. In 2013 Klaus-D. Langner was appointed to the corporate executive board of Gruenenthal GmbH as chief scientific officer where he stayed until 2018.

The company further announced that it secured additional funding for the phase IIa clinical study for its lead candidate AP-325 in chronic neuropathic pain.

Algiax Pharmaceuticals is a clinical-stage biotechnology company established in 2011.

It is dedicated to the discovery and development of innovative products to treat diseases with a high unmet medical need. Algiax' lead candidate AP-325 is a small-molecule GABAA receptor modulator in clinical development as a therapy for neuropathic pain.

Next to AP-325 Algiax has discovered novel GABAA receptor modulator compounds called Thioacrylamide derivatives. The company is advancing a selection of ThAcs derivatives from its discovery to preclinical characterisation.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jul 22, 2019
Words:287
Previous Article:Horizon Therapeutics Wins US FDA Acceptance of New Drug Application to Make Procysbi Available as Oral Granules in Packets.
Next Article:Transgene Receives MHRA Approval for a Clinical Trial of TG6002, a Next-generation Oncolytic Virus, Administered by Intrahepatic Artery Infusion in...

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters